Why Freshworks Stock Bumped Higher Today

The Motley Fool · 2d ago

Key Points

  • It'll replace a healthcare company that's being acquired.

  • The "index effect" was in play after the announcement.

Freshworks (NASDAQ: FRSH), an enterprise software company that has eagerly embraced artificial intelligence to power its solutions, posted a healthy gain on the stock market on Tuesday. That was mostly due to its inclusion in a prominent small-cap equity index.

Presence in a big small-cap index

After market close on Monday, S&P Dow Jones Indices announced that Freshworks is to replace healthcare stock BioLife Solutions as a component of the S&P SmallCap 600 index. BioLife is being acquired by peer company Repligen, which happens to be a component of the S&P MidCap 400 index.

Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

Person using a smartphone while seated at a desk with a laptop.

Image source: Getty Images.

The switch will be effective prior to market open this Thursday.

The index Freshworks is joining is one of a set of high-profile market gauges managed by S&P Dow Jones Indices. Arguably, the most influential and closely followed of these is the broad S&P 500 index.

Same as it ever was

In situations like this, it's always important for investors to bear in mind that index ascension has little to no effect on a company's operations or its financials. It does, however, make it a near-instant target for the many index funds currently popular with investors, as these are required to hold only component stocks of the S&P 500 index, S&P SmallCap 600 index, etc.

The "index effect" rarely lasts long, and I doubt this one will stretch very far. While becoming part of this well-known small-cap lineup is an achievement for Freshworks, this news alone shouldn't push investors into or out of the company's stock.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Repligen. The Motley Fool has a disclosure policy.